Yi-fan Wu
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Human umbilical cord mesenchymal stromal cells therapy for neuromyelitis optica spectrum disorder: a phase 1/2a trial.
Journal: Cell death and differentiation
Published: July 30, 2025
N6-Methyladenosine (m6A) Methylation Is Associated with the Immune Microenvironments in Acute Intracerebral Hemorrhage (ICH).
Journal: Molecular neurobiology
Published: June 16, 2023
Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients.
Journal: Frontiers in immunology
Published: June 11, 2022
Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUC-MSC-NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial.
Journal: Frontiers in neurology
Published: January 22, 2022
Comprehensive Analysis of N6-Methyladenosine (m6A) Methylation in Neuromyelitis Optica Spectrum Disorders.
Journal: Frontiers in genetics
Published: July 02, 2021
Lymphocyte Subsets Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders.
Journal: Neuroimmunomodulation
Published: May 29, 2021
Serum albumin level is associated with the severity of neurological dysfunction of NMOSD patients.
Journal: Multiple sclerosis and related disorders
Published: March 14, 2020
The differential expression of natural killer cells in NMOSD and MS.
Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
Published: July 19, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026